Dyne Therapeutics, Inc. (DYN)
- Previous Close
10.78 - Open
10.93 - Bid 11.05 x 500
- Ask 11.20 x 200
- Day's Range
10.74 - 11.24 - 52 Week Range
6.36 - 47.45 - Volume
1,914,400 - Avg. Volume
2,265,309 - Market Cap (intraday)
1.262B - Beta (5Y Monthly) 1.21
- PE Ratio (TTM)
-- - EPS (TTM)
-3.37 - Earnings Date Apr 30, 2025 - May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
47.86
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
www.dyne-tx.comRecent News: DYN
View More
Performance Overview: DYN
Trailing total returns as of 4/24/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DYN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DYN
View MoreValuation Measures
Market Cap
1.26B
Enterprise Value
644.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.00
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-50.20%
Return on Equity (ttm)
-88.03%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-317.42M
Diluted EPS (ttm)
-3.37
Balance Sheet and Cash Flow
Total Cash (mrq)
642.27M
Total Debt/Equity (mrq)
3.81%
Levered Free Cash Flow (ttm)
-189.47M